|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:baricitinib
|
|
gptkbp:activities
|
inhibiting Janus kinase enzymes
|
|
gptkbp:approves
|
gptkb:ulcerative_colitis
gptkb:rheumatoid_arthritis
gptkb:psoriatic_arthritis
atopic dermatitis
|
|
gptkbp:class
|
gptkb:Cloud_Computing_Service
|
|
gptkbp:clinical_trial
|
ongoing
completed
|
|
gptkbp:contraindication
|
active infections
severe liver disease
|
|
gptkbp:developer
|
combination therapies
ongoing research for new indications
|
|
gptkbp:discovered_by
|
early 2000s
|
|
gptkbp:example
|
gptkb:Ruxolitinib
gptkb:Baricitinib
gptkb:Tofacitinib
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Janus kinase (JAK) inhibitor
|
|
gptkbp:interacts_with
|
with corticosteroids
with biologics
with other immunosuppressants
|
|
gptkbp:invention
|
patented
generic versions available
|
|
gptkbp:is_monitored_by
|
liver function tests
lipid levels
blood counts
|
|
gptkbp:is_used_for
|
treating autoimmune diseases
|
|
gptkbp:manager
|
oral
injectable
|
|
gptkbp:marketed_as
|
gptkb:Xeljanz
gptkb:Olumiant
gptkb:Jakafi
Cibinqo
|
|
gptkbp:regulatory_compliance
|
FDA approved
EMA approved
|
|
gptkbp:research_areas
|
oncology
dermatology
immunology
|
|
gptkbp:side_effect
|
liver enzyme elevation
blood clots
increased risk of infections
|
|
gptkbp:targets
|
JA K1
JA K2
JA K3
TY K2
|